Lycera Secures $20,999,999 New Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=42a58218-9d4d-4bd3-88ce-ef1ae57e98a2&Preview=1 - Date
6/29/2012 - Company Name
Lycera - Mailing Address
2800 Plymouth Rd NCRC Building 26 Ann Arbor, MI 48109 - Company Description
Lycera is an early-stage pharmaceutical company developing first-in-class drugs to treat immune disorders. Lycera’s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway. - Website
http://www.lycera.com - Transaction Type
Venture Equity - Transaction Amount
$20,999,999 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. - M&A Terms
- Venture Investor
Undisclosed
